Artwork

Content provided by NPR. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NPR or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients

9:45
 
Share
 

Manage episode 306383885 series 2653190
Content provided by NPR. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NPR or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent Jon Hamilton explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.
Additional links:
- Jon's reporting on aducanumab: https://n.pr/3bDV0MY
- Jon's reporting on future Alzheimer's treatments: https://n.pr/3bDUsqo
You can always reach the show by emailing shortwave@npr.org.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
  continue reading

1055 episodes

Artwork
iconShare
 
Manage episode 306383885 series 2653190
Content provided by NPR. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NPR or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent Jon Hamilton explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.
Additional links:
- Jon's reporting on aducanumab: https://n.pr/3bDV0MY
- Jon's reporting on future Alzheimer's treatments: https://n.pr/3bDUsqo
You can always reach the show by emailing shortwave@npr.org.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
  continue reading

1055 episodes

Todos los episodios

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide